210 East Grand Avenue
South San Francisco, CA 94080
United States
650 457 2700
https://www.allogene.com
Secteur(s): Healthcare
Secteur d’activité: Biotechnology
Employés à temps plein: 232
Nom | Titre | Payer | Exercé | Année de naissance |
---|---|---|---|---|
Dr. Arie S. Belldegrun F.A.C.S., M.D. | Co-Founder & Executive Chairman | 649,1k | S.O. | 1949 |
Dr. David D. Chang M.D., Ph.D. | Co-Founder, President, CEO & Director | 994,6k | S.O. | 1960 |
Mr. Joshua A. Kazam | Co-Founder & Director | 260,5k | S.O. | 1977 |
Mr. Timothy L. Moore Ph.D. | Executive VP & Chief Technical Officer | 554,35k | S.O. | 1961 |
Dr. Zachary J. Roberts M.D., Ph.D. | Executive VP of Research & Development and Chief Medical Officer | 747,39k | S.O. | 1978 |
Mr. Geoffrey M. Parker | Executive VP & CFO | S.O. | S.O. | 1965 |
Mr. Earl M. Douglas Esq. | Senior VP, General Counsel, Compliance Officer & Corporate Secretary | S.O. | S.O. | 1963 |
Ms. Susan R. Lundeen | Chief People Officer | S.O. | S.O. | 1966 |
Ms. Christine Cassiano | Executive VP, Chief Corporate Affairs & Brand Strategy Officer | S.O. | S.O. | S.O. |
Yinlin Chen | Senior Vice President of Finance | S.O. | S.O. | S.O. |
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult patients with R/R CD19 positive B-cell acute lymphoblastic leukemia (ALL). The company also develops cemacabtagene ansegedleucel, an engineered allogeneic CAR T cell product candidate that targets CD19 for the treatment of large B-cell lymphoma; and is in Phase 1b clinical trial for the treatment of chronic lymphocytic leukemia. In addition, it is developing ALLO-715, an allogeneic CAR T cell product candidate that is in a Phase 1 clinical trial for treating R/R multiple myeloma; ALLO-605, an allogeneic CAR T cell product candidate that is in a Phase I clinical trial for the treatment of multiple myeloma; ALLO-647, an anti-CD52 monoclonal antibody; CD70 to treat renal cell cancer; ALLO-316, an allogeneic CAR T cell product candidate that is in Phase 1 clinical trial for the treatment of advanced or metastatic RCC; ALLO-329 for the treatment of certain autoimmune diseases; DLL3 for the treatment of small cell lung cancer and other aggressive neuroendocrine tumors; and Claudin 18.2 for the treatment of gastric and pancreatic cancer. The company has license and collaboration agreements with Pfizer Inc.; Servier; Cellectis S.A.; and Notch Therapeutics Inc. It also has a strategic collaboration agreement with The University of Texas MD Anderson Cancer Center for the preclinical and clinical investigation of allogeneic CAR T cell product candidates; and a strategic partnership with Foresight Diagnostics to develop MRD-based In-Vitro Diagnostic for use in ALPHA3. The company was incorporated in 2017 and is headquartered in South San Francisco, California.
L’ISS Governance QualityScore de Allogene Therapeutics, Inc. en date du 1 mai 2024 est 10. Les scores principaux sont Audit : 6; Société : 9; Droits des actionnaires : 8; Compensation : 10.